A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease
Cognitive Dysfunction
Mild Dementia

Interventions

DRUG: SAGE-718

Sponsor

Supernus Pharmaceuticals, Inc.